1.2-4.0 ϫ 10 T cells expressing the cell surface markers CD2, CD3, CD4, CD5, and CD7. Sequential treatment with fludarabine and cyclophosphamide failed to achieve disease remission. The results of serological tests for HIV type 1 and type 2 and human T lymphotropic virus type 1 and type 11 were negative.
Twenty-six doses of a planned 36 doses of thrice-weekly alemtuzumab (Campath-1H; Genzyme) were administered as salvage therapy, together with prophylactic cotrimoxazole and valaciclovir. Alemtuzumab is a humanized anti-CD52 monoclonal antibody that causes profound T and B lymphocyte depletion and moderate neutropenia; following administration of alemtuzumab, recovery of CD4 + T cells may take 11 year [1] .
Profound lymphopenia and neutropenia ensued, with nadir cell counts of cells/L and cells/L (reference 9 9 0.007 ϫ 10 0.5 ϫ 10 range, cells/L), respectively. Analysis of a bone 9 2.0-7.5 ϫ 10 marrow sample obtained by trephine biopsy 4 months after stopping alemtuzumab therapy showed complete disease remission.
In March 2004, the patient presented with a 3-week history of neck stiffness, headache, nausea, vomiting, photophobia, reduced visual acuity, and increasing dyspnoea. The patient's CD4 + T cell count at admission to the hospital was cells/L (reference range, cells/L), rep- 9 9 0.007 ϫ 10 0. Treatment with intravenous liposomal amphotericin (3 mg/ kg), which was started 1 day after admission to the hospital, was continued for 6 weeks. Flucytosine was not given because of its potentially toxic impact on bone marrow function, especially in the presence of renal failure. CSF, blood, and urine cultures had positive results for 37, 21, and 22 days, respectively. Intravenous fluconazole (administered at a dosage of 400 mg per day) was added to the treatment regimen 14 days after hospital admission because of the poor response to therapy. Repeated lumbar punctures and, subsequently, insertion of a ventricular-peritoneal shunt were required because of persistently elevated intracranial pressure. With the exception of persistent impairment of renal function (serum creatinine levels of ∼300 mmol/L; reference range, 30-115 mmol/L), the patient eventually made a good recovery, and he was discharged in June 2004 with a prescription for oral fluconazole (200 mg administered once per day).
The patient was readmitted to the hospital in January 2005-10 months after the acute presentation reported above-with a 2-week history of fever, dry cough, headache, and rash on the lower extremities. He had continued taking maintenance oral fluconazole (200 mg once per day) since discharge from the hospital 7 months earlier. On physical examination, the patient was febrile and tachypnoeic, but he was not hypoxic at rest. There was a painful, blanching maculopapular rash on the lower extremities that subsequently became confluent. The findings of respiratory and neurological examinations were normal, and there was no meningism. Diffuse interstitial shadowing was seen on a chest radiograph, and a high-resolution CT of the lungs showed ground glass opacities consistent with alveolar inflammation. Examination of CSF samples revealed a WBC count of ! cells/mL and normal protein and The patient's fever and respiratory symptoms resolved within 2 weeks with no additional therapy, and the rash gradually resolved over the course of the following month. The patient was admitted to the hospital again 3 months later with a generalized pruritic papulo-pustular rash, pleural effusion, acute renal deterioration, and moderate hypercalcemia, with a corrected serum calcium concentration of 2.97 mmol/L (reference range, 2.15-2.60 mmol/L). He had continued taking oral fluconazole throughout this period. Pleural fluid showed a lymphocyte count of cells/L, with mixed phenotype on 9 0.54 ϫ 10 flow cytometry and negative fungal and bacterial culture results.
The patient's CD4 + T cell count had increased to 9 0.278 ϫ 10 cells/L (22% of total lymphocytes). Histopathological examination of a biopsied skin lesion revealed a mixed inflammatory cell infiltrate and scattered fungal cells. Cultures of the biopsied tissue were not performed. With the exception of a persistent pruritic rash that was treated with topical corticosteroids, the patient's symptoms gradually resolved over the following 3 weeks. Six months later, the patient remained well, receiving fluconazole maintenance therapy (200 mg once per day) with no evidence of disease recurrence, but with a persistent serum cryptococcal antigen titer of 1:1024.
Our patient initially presented with fulminant disseminated cryptococcosis in the context of profound cellular immunodeficiency. Subsequent presentations several months after recovery from this illness are likely explained by a C. neoformansspecific immune reconstitution inflammatory response, which has heretofore not been described following alemtuzumab therapy. Given that neither skin biopsy sample was submitted for culture, strict criteria for immune reconstitution syndrome (IRS) were not satisfied in our patient, but key clinical and laboratory features that have previously been described were present, and no viable organisms were isolated from any of the tissues examined.
Fever, pleuropulmonary involvement, and hypercalcemia with granulomatous inflammation have all been observed in cryptococcal IRS following HAART [2] , which may occur in up to 30% of HIV-infected patients with a history of cryptococcal meningitis [3] . Subcutaneous abscesses have also been described in these patients [4] , but cutaneous involvementas in our patient, who had microscopically evident cryptococcal cells and granulomatous inflammation characteristic of IRS in the dermis-has not, to our knowledge, been described. In the context of HIV-related immunodeficiency and HAART, risk factors for IRS include a low CD4 + T cell nadir, short time between onset of a clinically recognized opportunistic infection and immune recovery, and high antigenic load at the time of immune recovery [3, 5, 6] . Although the interval between the initial presentation and the onset of IRS was 10 months in our case, the CD4 + T cell count had recovered from a prolonged low nadir while there was still a high tissue antigenic load, as revealed by examination of a skin biopsy sample. Similarly delayed presentations with C. neoformans-related IRS have been reported following the initiation of HAART [2] .
Our case highlights some of the difficulties in the diagnosis of IRS, which is complicated by heterogenous presentation and lack of specific diagnostic laboratory tests. A positive diagnosis usually relies on the demonstration of a sterile inflammatory syndrome in the context of immune restoration, while the specific organism against which the response is directed may be demonstrated histopathologically [7] . As in our patient, primary cryptococcal infection in the severely immunocompromised host is characterized by an abundance of yeast cells and histiocytes with relatively little acute inflammatory response [8] , while C. neoformans-related IRS exhibits focal granulomatous inflammation and often morphologically compatible organisms that can usually not be cultured [2, 7] . Diagnostic criteria have been proposed for IRS following HAART [6] but have not been proposed for other contexts.
We believe this to be the first description of IRS following treatment with alemtuzumab, a potent T cell lympholytic agent that is increasingly used for the treatment of refractory hematological malignancies and autoimmune conditions. Opportunistic infections are well-recognized complications of treatment with alemtuzumab [1, 9] , and IRS following immune recovery may become an important cause of morbidity. Recent reports suggest that cryptococcal IRS may also occur in patients undergoing solid-organ transplantation [10] . Recognition of IRS with recovery from iatrogenic suppression of immunity is likely to become increasingly important to avoid unnecessary investigation and to prompt consideration of antiinflammatory therapy [11] .
